Newborn RSV immunization rates and reasons compared to family COVID-19 and influenza immunization status.

ABSTRACT:

Background

Respiratory syncytial virus (RSV) is a common viral infection with the potential for severe illness in infants, leading to thousands of pediatric hospitalizations annually. In late 2023, Beyfortus (nirsevimab), a long-acting monoclonal antibody, became available to provide passive RSV immunization for all newborns meeting eligibility criteria. This study aimed to explore parental decision-making regarding RSV immunization, particularly in comparison to family uptake of COVID-19 and influenza vaccines, within an urban, predominantly Medicaid population in North Philadelphia.

Methods

This qualitative study was conducted at Temple University Hospital and Temple Pediatric Care outpatient clinic. Semi-structured interviews were performed with 25 parents and primary car

SUBMITTER: Somers J 

PROVIDER: S-EPMC12265380 | biostudies-literature | 2025 Jul

REPOSITORIES: biostudies-literature